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Objective. To compare the efﬁcacy and safety of adalimumab versus inﬂiximab in an open-label prospective, compar-
ative, multicenter cohort study of childhood noninfectious chronic uveitis.
Methods. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening,
noninfectious active uveitis were enrolled, and received for at least 1 year inﬂiximab (5 mg/kg at weeks 0, 2, and 6, and
then every 6–8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was
achieved, the time of a ﬁrst relapse. Time to remission, time to steroid discontinuation, and the number of relapses were
also considered.
Results. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behc¸et’s
disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with
early-onset sarcoidosis, and 1 with Behc¸et’s disease) were recruited in the inﬂiximab group. Cox regression analysis did
not show statistically signiﬁcant differences between the two groups with regard to time to achieve remission and time
to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment
was shown (Mantel-Cox 2  6.83, P < 0.001). At 40 months of followup, 9 (60%) of 15 children receiving adalimumab
compared to 3 (18.8%) of 16 children receiving inﬂiximab were still in remission on therapy (P < 0.02).
Conclusion. Even if limited to a relatively small group, our study suggests that over 3 years of treatment, adalimumab is
more efﬁcacious than inﬂiximab in maintaining remission of chronic childhood uveitis.
INTRODUCTION
Noninfectious uveitis in childhood is a relatively uncom-
mon severe disease, with potential signiﬁcant long-term
complications such as cataracts, glaucoma, and eventually
blindness (1). For these reasons, refractory uveitis usually
requires early and aggressive treatment. Immunomodula-
tory therapy is often needed in order to preserve visual
acuity and to prevent signiﬁcant morbidity of chronic ste-
roid administration (2). Recently, tumor necrosis factor 
(TNF)–blocking agents have been used to treat chronic,
refractory uveitis in adulthood as well as in childhood (3).
Inﬂiximab, a chimeric human–mouse monoclonal anti-
body against TNF, intravenously administered, and ada-
limumab, a fully human monoclonal antibody against
TNF, subcutaneously injected, have increased the treat-
ment options, albeit in small series and with short fol-
lowup (4–11). We have recently shown that inﬂiximab
appears to be an effective treatment for uveitis in children,
but in our experience, its efﬁcacy seemed to wane over
time after 1 year of treatment (12).
However, the lack of evidence from head-to-head ran-
domized controlled trials (RCTs) limits our understanding
of the best treatment choices, as well as the time of insti-
tuting therapy and its duration (4). Up to now, no data
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from comparative studies were available about the efﬁcacy
and safety of these 2 anti-TNF agents.
We recently published in abstract form our single-
center, comparative cohort study, suggesting that adali-
mumab is as efﬁcacious as inﬂiximab in the treatment of
sight-threatening childhood uveitis; however, such a pilot
study was conducted in a too-small cohort and in a short-
term analysis (13).
The purpose of this study was to compare the efﬁcacy
and safety of adalimumab versus inﬂiximab in an open-
label prospective, comparative, multicenter cohort study
of childhood noninfectious chronic uveitis.
MATERIALS AND METHODS
Study design. We conducted an open-label prospective,
comparative case series study of pediatric patients with
refractory uveitis treated with adalimumab and inﬂiximab
for at least a 1-year period at 3 tertiary pediatric rheuma-
tology centers in Italy: Anna Meyer Children’s Hospital,
Florence; Institute of Child Health IRCCS Burlo Garo-
folo, Trieste; and Pediatric Clinic, University of Brescia,
Brescia.
Inclusion criteria. To be considered eligible for this
study, patients were required to have disease onset prior to
age 16 years, vision-threatening noninfectious uveitis that
was refractory to therapy with systemic corticosteroids
and at least 1 other immunosuppressive medication, or to
be intolerant to such therapy. “Refractory” was considered
persistently active uveitis for at least 3 months despite
systemic steroids and immunosuppressive treatment
(methotrexate [MTX] and/or cyclosporin A [CSA]).
Study and treatment protocol. At the time of enroll-
ment, medical history and complete rheumatologic and
ophthalmologic examinations were performed in addition
to a tuberculin puriﬁed protein derivative skin test and a
chest radiograph. After stopping the previous immunosup-
pressive therapy (except corticosteroids), eligible children
were consecutively enrolled and received 1 of 2 anti-TNF
treatments. Steroid therapy was maintained at a stable
dosage (prednisone 1–2 mg/kg/day) for at least 6 weeks,
and then tapered once remission was achieved with regard
to uveitis activity.
Inﬂiximab infusions were administered at the dose of 5
mg/kg at weeks 0, 2, and 6, and then every 6–8 weeks for
at least 1 year. MTX treatment at very low dosages (5–7.5
mg/week) was maintained and/or added to prevent the
formation of antiinﬂiximab autoantibodies. In order to re-
duce the number of possible covariables inﬂuencing our
outcome measures, an increased dose of inﬂiximab was
not permitted during the time of the protocol, whereas a
decreased interval of administration every 6 weeks, a con-
trolled covariable in our analysis, was allowed; therefore,
for patients with breakthrough inﬂammation initially
treated with infusions every 8 weeks, a rate escalation to
every 6 weeks instead of to a dose escalation was allowed.
The adalimumab group received the drug at 24 mg/m2
subcutaneously every 2 weeks for at least 1 year. In both
groups, therapy was withdrawn if major side effects/
complications due to the treatment increased and/or lack
of efﬁcacy appeared.
The choice of the TNF inhibitor was an opinion-based
decision of the treating ophthalmologist and rheumatolo-
gist in collaboration and on the basis on drug availability
at their center at the date of starting the anti-TNF therapy.
Before each inﬂiximab infusion, and every 30–45 days
for adalimumab, children received a routine assessment
consisting of a general physical examination, laboratory
evaluation with renal and liver function tests, complete
blood cell count and inﬂammation parameters, and a com-
plete ophthalmologic evaluation, including best-corrected
visual acuity on Snellen eye charts and slit-lamp exami-
nation, which was performed at study enrollment and
according to the degree of activity thereafter. Once uveitis
achieved remission, children underwent an ophthalmo-
logic evaluation at each assessment or otherwise on clini-
cal demand, as needed.
The exact same protocol was applied in the 3 centers.
Approval was obtained by each local ethics committee.
Parents or guardians gave their informed consent.
Patients. All of the patients in this series were recruited
from the Paediatric Rheumatology Units in Florence,
Brescia, and Trieste from June 2006 to November 2008.
During the same period of the study, our centers were
following a total of 164 pediatric patients with chronic
uveitis (112 females, 52 males, median age 6 years, range
3–18 years); 106 were associated with juvenile idiopathic
arthritis (JIA), 7 with Behc¸et’s disease, 1 with early-onset
sarcoidosis, and 8 with other connective tissue diseases
(systemic lupus erythematosus or mixed connective tissue
disease), while the other 42 had idiopathic uveitis.
Thirty-three patients (22 females, 11 males, median age
9.2 years, range 5.2–13.8 years) resulted in being eligible
for the study and were enrolled; 21 were recruited in
Florence, 9 in Trieste, and 3 in Brescia.
In 25 of 33 children, active uveitis was associated with
an underlying autoimmune disease: 22 JIA (11 oligoarticu-
lar, 7 extended oligoarticular, and 4 rheumatoid factor–
negative polyarticular), 1 early-onset sarcoidosis, and 2
Behc¸et’s disease. The other 8 children had idiopathic uve-
itis. Among 11 of 25 patients with secondary uveitis at
enrollment, the associated underlying disease was active
despite concomitant medications, while the remaining 14
patients were in remission on therapy with regard to the
associated disease, but not to uveitis.
Before anti-TNF treatments, all of the children had
presented with active uveitis: 42 of 66 involved eyes,
despite treatment with MTX at the dosage of 15 mg/m2/
week (n  21), CSA at the dosage of 3 mg/kg/day (n  8),
and the combined administration of MTX and CSA (n 4).
Three children with JIA in articular remission receiving
etanercept (0.4 mg/kg twice a week) experienced uveitis
while on this treatment: due to its refractory course, a
3-month trial of concomitant MTX therapy was added, but
it resulted in being ineffective; therefore, concomitant
therapy was stopped and they were eligible for the study.
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Due to active uveitis along with topical steroids during
the acute phase, all of the children were also receiving oral
prednisone (1–2 mg/kg/day) at stable doses for at least 6
weeks (range 45–55 days).
Main outcome measures. Absence or recurrence rate of
uveitis throughout the study period, visual acuity pre– and
post–anti-TNF treatment, tapering of steroid medication,
and safety of administered drugs were recorded.
In order to compare their potential long-lasting effect on
maintaining remission, the primary outcome was to assess,
once remission was achieved, the time of a ﬁrst relapse
during treatment. In addition, secondary outcomes were to
compare, once anti-TNF treatment was started, time to
uveitis remission, time to steroid discontinuation, and the
number of uveitis relapses.
Anterior chamber cells and ﬂare were graded according
to the Standardization of Uveitis Nomenclature Working
Group grading schemes for anterior chamber cells and ﬂare
criteria (14). Intraocular inﬂammation was considered “ac-
tive” or uncontrolled if the inﬂammatory activity was
grade 1 at any examination.
Uveitis was deﬁned as improved, and adalimumab or
inﬂiximab as successful, when its activity decreased by 2
steps in the level of inﬂammation (anterior chamber cells
and/or vitreous haze) or decreased to grade 0. For assess-
ing visual acuity, Snellen charts were used and “normal”
acuity was deﬁned as at least a best-corrected visual acuity
of 20/25 (0.8 in a decimal scale  0.10 in a logMAR
format). “Improved” visual acuity was deﬁned as a dou-
bling of the visual angle (converted into a logMAR format)
in at least 1 eye. Conversely, “worsened” visual acuity was
deﬁned as a halving of the visual angle at a logMAR format
from baseline in at least 1 eye (corresponding to an in-
crease or decrease of 3 lines on a decimal scale with a
logarithmic chart) (15).
Statistical analysis. All of the results are expressed as
the mean  SD or median. Mann-Whitney U test, Wilcox-
on’s signed rank test for paired samples, chi-square tests,
and Fisher’s exact test, when appropriate, were used to
compare data.
An a priori power analysis was completed using the G
Power program (16). Two-tailed P values were employed.
Considering current data of refractory uveitis in children,
a large expected difference was estimated for the sample:
the effect size F  0.40, as per Cohen (17). In addition,
power was set at 0.95, meaning there would be a 95%
probability of reaching statistical signiﬁcance if the ob-
tained differences were truly present in the population.
Results from the power analysis showed that 32 partici-
pants, 16 for each arm, in all groups combined would be
required.
The following data, entered into a customized uveitis
database, were considered as variables for correlations and
as covariates for the survival curves: age at the study
entry/age at the initiation of anti-TNF therapy, sex, asso-
ciated autoimmune disease, disease duration, age at uve-
itis onset, uveitis duration, active uveitis duration, time
interval between the uveitis onset and the initiation of
anti-TNF, drug therapy administration (number and fre-
quency), concomitant medications, previous cumulative
corticosteroid dose and its duration, previous disease-
modifying antirheumatic drug treatment duration, number
of previous ﬂares, number of patients with eye complica-
tions due to chronic uveitis (including glaucoma, syn-
echia, band keratopathy, cystoid macular edema, vitreitis,
and cataract), and followup time.
Before each eligible subject was recruited, an inclusion
criteria second revision was performed by the Florence
center, which acted as study coordinator and data man-
agement.
Pearson’s and Spearman’s correlation tests were used to
determine correlation coefﬁcients for different variables.
In order to identify predictors of outcome, Cox regression
model and Kaplan-Meier curves were constructed, each 1
at the mean of the covariates reported above. Nonparamet-
ric tests were used, where necessary, due to the small size
of our groups and to the skewness of our data. Levels of P
values less than 0.05 were considered statistically signiﬁ-
cant. All analyses were performed with the SPSS package
for Windows, version 13.0.
RESULTS
Sixteen children (10 females, 6 males), 12 affected by JIA,
3 by idiopathic uveitis, and 1 by Behc¸et’s disease, were
recruited in the adalimumab cohort. Seventeen children
(10 females, 7 males), of whom 10 were affected by JIA, 5
by idiopathic uveitis, 1 by early-onset sarcoidosis, and 1
by Behc¸et’s disease, were enrolled in the inﬂiximab group.
As reported in Table 1, demographic information and
other reported variables in the statistical analysis section
did not differ between the 2 groups.
No patient in the inﬂiximab group had previously re-
ceived adalimumab, and vice versa. The total median fol-
lowup time receiving treatment was signiﬁcantly higher in
the inﬂiximab group than in the adalimumab group (31
months, range 18–40 months versus 22 months, range
14–36 months; P  0.001).
During the ﬁrst year of treatment after starting anti-TNF
therapy, 31 of 33 children achieved complete remission:
15 of 16 receiving adalimumab over a median period of 12
weeks (range 8–16 weeks) and 16 of 17 receiving inﬂix-
imab over a median period of 10 weeks (range 6–18 weeks;
not signiﬁcant). In 2 patients, both with JIA, the anti-TNF
therapy (1 receiving adalimumab and 1 receiving inﬂix-
imab) was not able to control eye inﬂammation during the
ﬁrst year of treatment; therefore, they never achieved re-
mission and were considered “nonresponders.” They
therefore resulted in being eligible for the inclusion crite-
ria (refractory uveitis), but not for our outcome measures
(absence or recurrence of uveitis), and therefore were ex-
cluded from the long-term survival analysis.
In regard to our primary outcome measure, at the mean
of the abovementioned covariates, including the total
length of followup time of the 2 cohorts, Cox regression
analysis showed a higher probability of uveitis remission
on adalimumab therapy than inﬂiximab therapy during
the time of treatment (log-rank, Mantel-Cox 2  6.83, P 
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0.001) (Figure 1). At 40 months of followup, which was the
longest period common to the 2 groups, 9 (60%) of 15
children receiving adalimumab compared to 3 (18.8%) of
16 children receiving inﬂiximab were still in remission on
therapy (likelihood ratio 5.72, P  0.02).
Considering the secondary outcomes, at the mean of the
above reported covariates, survival Cox regression analysis
did not show statistically signiﬁcant differences between
the 2 treatment groups with regard to time to remission
and time to steroid discontinuation (Figures 2A and B).
Twenty-six children (13 receiving inﬂiximab and 13 re-
ceiving adalimumab) were able to stop steroid administra-
tion during the ﬁrst 6 months from the start of anti-TNF
therapy; however, all 31 responders discontinued steroid
administration before 1 year of treatment, with a median
time of 3 months both for the adalimumab group (range
1–10 months) and the inﬂiximab group (range 1–12
months).
In all 31 responders, no relapse of uveitis occurred dur-
ing the ﬁrst year of treatment, whereas before starting
anti-TNF therapy, the median number of relapses was 4
per year (range 2–6 per year) for adalimumab and 3 per
year (range 2–7 per year) for inﬂiximab. After the 1-year
followup visit, among responders, 12 (80%) of 15 receiv-
ing adalimumab and 13 (82%) of 16 receiving inﬂiximab
met the criteria for improved visual acuity, corresponding
to 19 (63%) of 30 eyes and 20 (62.5%) of 32 eyes, respec-
tively (not signiﬁcant). At the 1-year followup, the number
of patients as well as the number of eyes within a “normal
visual acuity” was signiﬁcantly higher than before treat-
ment both for the adalimumab (13 of 15 patients versus 3
of 15 patients; P  0.05 and 21 of 30 eyes versus 9 of 30
eyes; P  0.03) and inﬂiximab groups (14 of 16 patients
versus 3 of 16 patients; P  0.05 and 25 of 32 eyes versus
9 of 32 eyes; P  0.02). However, at 1 year of treatment, no
signiﬁcant differences were detected between the 2 treat-
ment arms. None of the patients were amblyopic and re-
fractive errors were corrected by means of glasses or con-
tact lenses. All recorded variations in best-corrected visual
acuity were therefore related to disease activity and no
clearance of media was recorded.
Among children who relapsed, at 40 months of fol-
lowup, the median number of relapses resulted as statisti-
cally signiﬁcantly higher in the inﬂiximab group than in
the adalimumab group (3, range 1–5 versus 1, range 1–3; P
 0.001). At 40 months of followup, the median number of
relapses per year receiving inﬂiximab did not show a sta-
tistically signiﬁcant difference than before inﬂiximab (3,
range 1–5 versus 3, range 2–7; not signiﬁcant); on the
Table 1. Comparison of variables for correlations and as covariates for the survival curves in 33 children with refractory
chronic uveitis receiving adalimumab and receiving inﬂiximab*
Adalimumab
(n  16)
Inﬂiximab
(n  17) P
Age, years 8.4 (6.4, 12.3) 10.4 (5.2, 13.10) 0.19
Sex, female (%)/male 10 (62.5)/6 10 (58.8)/7 0.82
Age at onset of uveitis, years 5.4 (2.2, 11.4) 5.8 (2.4, 12.2) 0.43
Uveitis history duration, months 34 (10, 68) 29 (12, 84) 0.73
Children with associated autoimmune disease, no. (%) 13 (81.2) 12 (70.5) 0.68
No. (%) with active underlying disease 5 (31.2) 6 (35.3) 0.69
Age at onset of underlying disease, years 2.6 (1.2, 12.2) 2.4 (1.3, 12.5) 0.29
Disease duration at uveitis onset, months 8 (13, 50) 10 (16, 28) 0.74
Time interval between uveitis onset and anti-TNF
starting, months
48 (6, 75) 40 (12, 84) 0.71
Corticosteroids
Oral dose, mg/kg 1.2 (0.25, 2) 1.3 (0.20, 2) 0.73
Previous oral cumulative dose, mg 960 (560, 3,400) 840 (300, 4,400) 0.82
Previous administration duration, months 9 (2, 16) 8 (3, 22) 0.85
Previous DMARD treatment duration, months 24 (8, 48) 21 (9, 66) 0.62
Active uveitis cumulative duration, months 6 (3, 11) 5 (3, 10) 0.42
No. of previous ﬂares 4 (2, 6) 3 (2, 7) 0.54
No. (%) of patients with eye complications due to
chronic uveitis
5 (31.2) 4 (23.5) 0.70
* Continuous variables are expressed as the median (range) unless otherwise indicated. Anti-TNF  anti–tumor necrosis factor ; DMARD 
disease-modifying antirheumatic drug.
Figure 1. Survival curves of the time up to the ﬁrst uveitis relapse
on therapy after achieving remission (months) in the adalimumab
group and in the inﬂiximab group. On the y-axis, the probability
of a patient being without relapse on anti–tumor necrosis factor 
therapy is shown (P  0.001).
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contrary, the median number of relapses per year receiving
adalimumab resulted as signiﬁcantly lower than before
treatment (1, range 1–3 versus 4, range 2–6; P  0.001).
The total number of relapses during followup, limiting
the analysis to a 40-month total period, correlated with the
duration of inﬂiximab treatment (rs  0.85, P  0.003), but
not with adalimumab treatment (P  0.81).
In addition, we performed a subgroup analysis limited
just to children with JIA with regard to our primary and
secondary outcomes, and we obtained the same statistical
results. Cox regression analysis showed a higher probabil-
ity of uveitis remission on adalimumab therapy during
the time of treatment entered for each cohort (log-rank,
Mantel-Cox 2 4.12, P 0.03); at 20 months of followup,
which was the longest period common to the 2 groups, 7
(63.6%) of 11 children receiving adalimumab compared to
1 (11.1%) of 9 children receiving inﬂiximab were still in
remission on therapy (likelihood ratio 4.24, P  0.02).
Again, we did not observe any statistical differences be-
tween the 2 groups with regard to the time to uveitis
remission and the time to steroid discontinuation.
During the study period, 3 children with JIA developed
a concomitant ﬂare of arthritis associated with eye relapse,
achieving a complete joint remission soon after the subse-
quent inﬂiximab infusion in 2 children and after 3 adali-
mumab doses in the third patient.
Four patients developed complications attributable to
inﬂiximab, and 1 had to discontinue treatment. Two chil-
dren experienced 1 episode of leukopenia, and in another,
liver enzymes increased 3-fold; both of these adverse
events were transient and they disappeared before the
following infusion without the need to stop therapy. At the
thirteenth infusion, 1 patient exhibited a severe infusion
reaction (rash, hypotension, and respiratory distress) and
stopped the therapy. Among adalimumab patients, 5 re-
ported pain/burning/discomfort at the injection site, with
concomitant local reaction in 2. No severe reaction requir-
ing drug discontinuation and no signiﬁcant laboratory ab-
normalities occurred.
DISCUSSION
Even if limited to a relatively small group, this compara-
tive cohort study suggests that adalimumab is more efﬁca-
cious than inﬂiximab in a 3-year period of treatment of
sight-threatening childhood uveitis, with regard to time of
the ﬁrst ﬂare, once remission has been achieved.
To our knowledge, RCTs comparing adalimumab versus
inﬂiximab have not been published to date, and our study
represents the ﬁrst prospective cohort comparative study
on this topic.
Starting with a superiority study design, we assumed
that the null hypothesis (H  0) is true; therefore, we
assumed that there were not differences in efﬁcacy and
safety between these 2 anti-TNF strategies in treating
childhood chronic uveitis.
Our analysis indeed seems to accept the experimental
hypothesis, suggesting that adalimumab during the ﬁrst
year of treatment has the same efﬁcacy as inﬂiximab, but
during a longer followup shows a higher probability of
maintaining remission. If our results are duplicated in a
larger cohort, the evidence of this drug comparison on
remission duration will reach a level IIb, converse of what
is currently known on this topic (evidence level III). There-
fore, when facing childhood-refractory chronic uveitis in
clinical practice, the therapeutic strategy could be as-
sessed using an evidence-based choice; with the same rate
of efﬁcacy but with a longer remission duration, it would
be preferable to choose a drug that is easier to manage
(adalimumab) than a drug that rather requires intravenous
administration and hospitalization (inﬂiximab). This strat-
egy would result in better patient compliance and in a
longer therapeutic efﬁcacy.
Before drawing ﬁrm conclusions from our results, some
caveats have to be discussed and considered. First, due to
the rarity of the disease (refractory childhood chronic uve-
itis), the small sample size limits our study results. In
addition, the inherent selection bias of 3 tertiary referral
centers must be taken into account, and children enrolled
Figure 2. A, Survival curves of the time to achieve ocular activity remission (weeks) in the adalimumab group and in the inﬂiximab group.
On the y-axis, the probability of a patient being with active uveitis on anti–tumor necrosis factor  therapy is shown (P 0.83). B, Survival
curves of the time to steroid discontinuation (months) in the adalimumab group and in the inﬂiximab group. On the y-axis, the probability
of a patient being on steroid treatment is shown (P  0.71).
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represent a heterogeneous population, with possible vari-
able responses to treatment. The heterogeneity of the sam-
ple cohort, with regard to the underlying disease, might
also affect the results of our study; however, we also re-
ported a subcohort analysis, limited to the JIA children
only, showing the same statistical results for efﬁcacy, ste-
roid sparing, and rate of recurrence at followup.
Notably, another shortcoming of our study is the type of
treatment assignment used; it was not randomly assigned
but chosen based on current knowledge of anti-TNF treat-
ment in childhood chronic uveitis and drug availability:
an evidence level III, which means expert opinion, clinical
experience, or descriptive study.
Even if prospective, the present study was not an RCT,
and we perfectly recognize the scientiﬁc strength of an
RCT versus a comparative cohort study. We have consid-
ered this topic during the study design formulation, but at
this time, due to the actual knowledge on childhood
chronic uveitis, we have also considered performing in
advance an open-label pilot study as a prerequisite, since
there was little evidence coming from the current litera-
ture to perform a double-blinded randomization in chil-
dren, especially when dealing with this sight-treating and
potentially disabling disease. In addition, an evidence
level IIb could be better than actual knowledge and could
be the basis for the study design of a more extensive and
complete multicenter RCT on this topic.
However, our study is a multicenter study coming from
3 different units, and this strategy can in part reduce the
bias due to a “subjective” decision: a supposedly better
drug for more severely affected patients. In addition, be-
cause we have enrolled just “refractory uveitis,” we have
also considered that our study population is a “selected
population,” thus potentially inferring data through a se-
lection bias; we thought to minimize this effect bias by
performing statistical comparisons as much as possible,
due to the sample size, in homogenous cohorts.
With regard to the long-term remission, the longer fol-
lowup treatment period in the inﬂiximab group when
compared to the adalimumab group could affect the data,
resulting in a nonhomogenous comparison; however, it
has been considered as a covariate for the survival curves,
therefore overweighting its potential effect size. The ana-
lysis was moreover limited to the 40-month followup,
which was the longest period common to the 2 groups;
moreover, as shown in Figure 2, the number of subjects in
remission had a higher result in the adalimumab group
already before the 20-month period.
Inﬂiximab has been found to be effective as a short-term
immunosuppressive agent in noninfectious uveitis in
childhood, with increasing frequency in JIA-associated
uveitis and in Behc¸et’s disease (3,18–22). Nonetheless, its
efﬁcacy seems to wane over time, as we recently reported
in a prospective case series of 15 children with childhood
chronic uveitis followed for a period of 2 years (12), and as
data from this prospective multicenter cohort seem to con-
ﬁrm. In agreement with these data, Tugal-Tutkun et al
reviewed the medical records of 20 children with uveitis
who had been treated with inﬂiximab; although all of the
patients received concomitant immunosuppressive ther-
apy, 4 patients showed uveitis reactivation due to loss of
efﬁcacy at 10–36 months of inﬂiximab therapy (23). Nota-
bly, higher doses of inﬂiximab have then also been used in
treating refractory uveitis in long-term followup. Kahn et
al (5) used 10 to 20 mg/kg at each infusion and Rajaraman
et al (24) similarly obtained a good control of ocular in-
ﬂammation over a 48-week period, increasing the dose to
18 mg/kg. Recently, Ardoin et al (25) reported that a me-
dian maintenance inﬂiximab dose of 8.2 mg/kg was nec-
essary in order to control uveitis over a 26-month followup
period.
Conversely, Suhler et al, in an open-label 2-year pro-
spective study on inﬂiximab, reported a high rate of dis-
continuation of almost 65% because of the occurrence of
signiﬁcant adverse events, inefﬁcacy, and patient compli-
ance (26).
To date, no placebo RCTs have been performed in order
to assess the efﬁcacy of inﬂiximab in pediatric uveitis.
Adalimumab has been suggested to be the most efﬁca-
cious TNF blocker for childhood uveitis (11), even
though larger trials are needed to conﬁrm this hypothesis.
Vazquez-Cobian et al have described 14 children with
uveitis (9 JIA-associated and 5 idiopathic) treated with
adalimumab for an average of 18.1 months: reduced in-
ﬂammation was reported in 21 (80.8%) of 26 eyes, a stable
situation in 4 eyes (15.4%), and worsening in 1 eye (3.8%).
No adverse effects occurred (9). As in our series, Biester et
al (10) found that adalimumab was effective in 10 of 16
patients with JIA-related uveitis and in 16 of 18 children
with idiopathic uveitis, with no acute side effects or a high
incidence of infections. In 15 children, it also allowed the
discontinuation of systemic corticosteroids, and in the
remaining 3 patients a reduction to low doses was
achieved. Tynja¨la¨ et al recently reported their experience
of 20 children with JIA and chronic uveitis treated with
adalimumab (27). Seventeen patients (85%) had polyartic-
ular JIA and 19 (95%) had previously received another
anti-TNF agent. The mean duration of adalimumab ther-
apy was 18.7 months. Seven patients (35%) showed im-
proved activity, 1 (5%) showed worsening activity, and in
12 (60%), no change was observed. Those with improved
activity were younger and had shorter disease duration.
The mean number of ﬂares per year decreased from 1.9 to
1.4 during adalimumab treatment. Adverse events were
not observed. Seven patients discontinued adalimumab
during followup: 6 because of inefﬁcacy and 1 because of
remission of uveitis (27).
In agreement with the aforementioned studies, our data
suggest that adalimumab is rapidly effective and well tol-
erated, representing an appealing steroid-sparing agent
with no signiﬁcant adverse events, irrespective of the un-
derlying associated disease.
As far as we know, this is the ﬁrst prospective compar-
ative study between these 2 anti-TNF agents in childhood
chronic uveitis, showing for adalimumab superior activity
in maintaining remission over a relatively long-term treat-
ment period. Of note, converse to most of the previously
published studies, our data came from a prospective,
rather than retrospective, comparative case series, repre-
senting the longest prospective followup available study
for adalimumab therapy in childhood-refractory chronic
uveitis.
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However, additional long-term prospective case series
are needed to better understand the correct anti-TNF
strategy for childhood-refractory chronic noninfectious
uveitis, and a randomized clinical trial might be advocated
on this topic. A recently published case series suggested
that in case of refractory uveitis with loss of initial clinical
response to 1 biologic agent, switching to another agent
can restore control of intraocular inﬂammation and may
help to control systemic symptoms (28). Accordingly, Bi-
ester et al also reported favorable results in each “direc-
tion” among the current available anti-TNF options: an
achievement and maintenance of remission of ocular in-
ﬂammation on adalimumab, when inﬂiximab or etaner-
cept were not effective or not tolerated, but also efﬁcacy of
etanercept or inﬂiximab in case of adalimumab failure, or
fair and weak control of ocular disease (10).
In conclusion, even if limited to a small group, this
comparative cohort study on anti-TNF treatment for
sight-threatening childhood uveitis suggests that adali-
mumab is as efﬁcacious as inﬂiximab in a short-term pe-
riod, but maintains in remission for a longer period and
with a higher rate. Prospective RCTs are needed to verify
this ﬁnding.
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